Drug intelligence / Profile preview

CTM-MSC

Development stage: Unknown
Lead developer: CytoMed Therapeutics China
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

CTM-MSC is an injectable allogeneic cell therapy candidate consisting of mesenchymal stem cells (MSCs) derived from human umbilical cord tissue. Developed by CytoMed Therapeutics, the therapy is designed to treat cartilage injuries by utilizing the regenerative and immunomodulatory properties of MSCs. The treatment approach may also involve the use of CTM-MSC conditioned media, which contains a secretome of growth factors and cytokines that support tissue repair and reduce inflammation. In early 2024, CytoMed entered into a collaboration with Sengkang General Hospital in Singapore to advance the program through in vivo studies and into a Phase I clinical trial.

Other names: Allogeneic umbilical cord-derived mesenchymal stem cell therapyCytoMed MSC

Beyond the preview

Go deeper on CTM-MSC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTM-MSC.

Explore the full profile